Nucleoside reverse transcriptase inhibitors (zidovudine and stavudine) side-effects in people living with human immunodeficiency virus/acquired immunodeficiency syndrome attending the antiretroviral treatment center of B.J. Medical College and Civil Hospital at Ahmedabad, Gujarat, India

Shah, Asha; Nihalani, Umesh; Kavina, Burzin

doi:10.4103/0253-7184.120571

Cited by 1 publication

(1 citation statement)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…При этом факторами риска развития анемии авторы считают женский пол и уровень CD4 менее 200 кл/мкл [14]. В исследованиях A. N. Shahи соавт., посвященных изучению токсичности зидовудина и ставудина как представителей группы НИОТ, частота развития анемия при назначении пациентам зидовудина составила 13,8%, при этом средняя продолжительность развития анемии составила 3 месяца (12 недель) [15]. Частота развития анемии как осложнения применения препаратов группы НИОТ в аналогичном исследовании, проведенном в Индии D. Agarwal и соавт., составило 16,2% случаев.…”

unclassified

Monitoring the safety of antiretroviral drugs in patients with HIV infection

Матвеев¹,

Крашенинников²,

Егорова³

et al. 2021

VIČ-infekc. immunosupr.

View full text Add to dashboard Cite

The antiretroviral therapy is a lifelong use of a combination of three or more antiretroviral drugs (ARVDs). One of the factors contributing to a significant decrease in patients’ adherence to treatment is the high toxicity of ARVs.The aim of the study is to study the safety of antiretroviral drugs retrospectively and based on spontaneous reports about adverse drug reactions (ADRs) inputted in the ARCADe database.Materials and method. The objects of our research were the 649 spontaneous messages about ARVDs recorded in the regional electronic database (register) of spontaneous messages for period 01 January 2009 — 31 December 2018.Results. Most often, ADR were registered with the use of combined ARVD and non-nucleoside reverse transcriptase inhibitors. Zidovudine and Efavirenz were the leaders in terms of the incidence of ARV ADR. Among the combined anti-HIV drugs, the most frequently ADR were associated with the use of a Lamivudine and Zidovudine combination.Conclusion. Long-term use of ARVs requires regular monitoring of adverse reactions, which will improve the quality of life of patients with HIV infection and significantly increase their compliance with antiretroviral pharmacotherapy.

show abstract

unclassified